Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
Remibrutinib showed sustained efficacy and a consistent, favorable long-term safety profile in patients with CSU remaining symptomatic despite second-generation H<sub>1</sub>-antihistamines.
Authors
- Noriko Seko
- Michihiro Hide (ORCID: https://orcid.org/0000-0002-1569-6034)
- Michael Palumbo (ORCID: https://orcid.org/0000-0001-7483-0849)
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Gordon Sussman (ORCID: https://orcid.org/0000-0002-2202-2513)
- R. Szalewski
- Vipul Jain (ORCID: https://orcid.org/0000-0002-4421-5535)
- Bin Yang (ORCID: https://orcid.org/0000-0002-0275-3722)
- Giselle Mosnaim (ORCID: https://orcid.org/0000-0002-9874-3472)
- Ekin Şavk (ORCID: https://orcid.org/0000-0002-9318-1378)
- Ana Maria Giménez‐Arnau (ORCID: https://orcid.org/0000-0001-5434-7753)
- Sarbjit S. Saini (ORCID: https://orcid.org/0000-0001-8522-2742)
- Artem Zharkov
- Martin Metz (ORCID: https://orcid.org/0000-0002-4070-9976)
- E.D. Martzloff
- A. Khemis (ORCID: https://orcid.org/0000-0003-1329-5875)
- Irena Walecka-Herniczek
- Claire Field
- Sibylle Haemmerle
- Pengpeng Wang (ORCID: https://orcid.org/0000-0003-2160-9360)
- P.G.P Machado
- K. Lheritier
Institutions
- Novartis (Switzerland) (CH)
- NorthShore University HealthSystem (US)
- Johns Hopkins University (US)
- Universitat Pompeu Fabra (ES)
- University of Toronto (CA)
- Johns Hopkins Medicine (US)
- Humboldt-Universität zu Berlin (DE)
- Novartis (China) (CN)
- Hiroshima City Asa Citizens Hospital (JP)
- Novartis (Japan) (JP)
- Novartis (United States) (US)
- Probity Medical Research (CA)
- Central Clinical Hospital (PL)
- Asthma Association (BG)
- Allergy Associates Research Center (US)
- Novartis (Ireland) (IE)
- Southern Medical University (CN)
- Adnan Menderes University (TR)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology
- Published
- 2025-10-18
- DOI
- https://doi.org/10.1016/j.jaci.2025.09.028
- Citations
- 3
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.41